SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (5253)9/3/1998 1:25:00 PM
From: Bhag Karamchandani  Read Replies (1) of 6136
 
Rick: I very much hope and want AG3340 to do well, first and foremost, for the sake of patients and hopefully for investors. But I don't think hoping is enough. I have come across more promising pre-clinical and PI result announcements.
"The preclinical and phase I data convinced AGPH, the FDA and at least one private investor (me) that 3340 was worth testing in expanded trials"
FDA could hardly say no to a drug that has acceptable safety profile with the potential to prolong life of terminal patients by even a few months.

I would very much appreciate your personal but specific reasons for concluding that AG3340 was worth testing- beyond repeating the very limited and modest results announced by AGPH. Thanks.

PS If AGPH is simply being ultra conservative then that is laudable and perhaps the concerns raised here are premature. But they were quick to tout AG3340 after the Entremed story surfaced. Ambivalent at the very least.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News